Log in
E-mail
Password
Remember
Forgot password ?
Become a member for free
Sign up
Sign up
Settings
Settings
Dynamic quotes 
OFFON

4-Traders Homepage  >  Equities  >  Nyse  >  Johnson & Johnson    JNJ

SummaryQuotesChartsNewsAnalysisCalendarCompanyFinancialsConsensusRevisions 
News SummaryMost relevantAll newsSector newsTweets 

Biomet To Settle With DOJ, SEC On Bribery Charges For $22.7Mln

share with twitter share with LinkedIn share with facebook
share via e-mail
0
03/26/2012 | 05:50pm CEST

Medical-device company Biomet Inc. has agreed to pay about $22.7 million to settle civil and criminal charges stemming from allegations the company's units and agents bribed public doctors in Argentina, Brazil and China for nearly a decade to win business, the Department of Justice and the Securities and Exchange Commission said Monday.

The agencies allege that Biomet and its four units paid bribes from 2000 to August 2008, and employees and managers at all levels of the parent company and the units were involved, along with distributors. Biomet's compliance and internal audit functions failed to stop the payments to doctors even after learning about the illegal practices, the agencies alleged.

A Biomet representative wasn't immediately available for comment.

Biomet agreed to pay a $17.3 million criminal penalty for allegedly violating the Foreign Corrupt Practices Act. In its Justice Department agreement, it is required to implement rigorous internal controls, cooperate fully with the Justice Department and retain a compliance monitor for 18 months. Additionally, the company will pay $5.4 million in disgorgement of profits and prejudgment interest, as part of its separate SEC settlement.

Biomet, a privately held company that sells products used by orthopedic surgeons, is the third medical device firm to enter into a settlement with government agencies as part of the SEC and Justice Department's ongoing global investigation into medical-device companies allegedly bribing publicly employed physicians. Previously, Johnson & Johnson (>> Johnson & Johnson) and Smith & Nephew PLC (SNN, SN.LN) agreed to pay criminal penalties and entered into deferred prosecution agreements related to similar investigations, the Justice Department said.

In January, Biomet said its fiscal second-quarter loss widened as a drop in spine and bone-healing sales as well as higher costs masked the company's revenue growth.

-By Ben Fox Rubin, Dow Jones Newswires; 212-416-3108; [email protected]

Stocks mentioned in the article : Johnson & Johnson
share with twitter share with LinkedIn share with facebook
share via e-mail
0
Latest news on JOHNSON & JOHNSON
03:00p JOHNSON & JOHNSON : U.S. FDA Grants Priority Review of XARELTO® (rivaroxaban) sN..
10:17a DXB ENTERTAINMENTS : DDB Dubai names new managing director
06/27 JOHNSON & JOHNSON : Personalized nutrition co DayTwo raises $12m
06/26 JOHNSON & JOHNSON : Advanced sterilization products receives fda clearance for w..
06/26 JOHNSON & JOHNSON : Breakfast Technical Briefing on Drug Makers Stocks -- Pfizer..
06/26 JOHNSON & JOHNSON : Releases 2016 Health for Humanity Report
06/26 JOHNSON & JOHNSON : Trump picks sports billionaire as new US ambassador to Brita..
06/24 JOHNSON & JOHNSON : American Dental Hygienists' Association Honors Dental Hygien..
06/24 DXB ENTERTAINMENTS : DDB Dubai appoints Iris Minnema as MD
06/23 JOHNSON & JOHNSON : State investigates drug makers
More news
Sector news : Pharmaceuticals - NEC
06:52p UK blue chips led lower by Hargreaves as strong pound takes toll
06:40pDJVECTURA : In Asthma Collaboration With Novartis's Sandoz
05:33pDJGLAXOSMITHKLINE : Announces US Filing For Mepolizumab
01:10pDJMERCK AND : Today's Top Supply Chain and Logistics News From WSJ
08:35a Factbox - Companies hit by global ransomware attack on June 27
More sector news : Pharmaceuticals - NEC
News from SeekingAlpha
01:01p Globus Medical Has Wobbled A Bit, But Still On Good Footing
08:44a FDA grants Priority Review status for lower dose of J&J's Xarelto
06/27 TIGENIX : This Stem Cell Pioneer Is Up 40% Since IPO With More Upside To Come
06/27 Kala Pharmaceuticals Files For $86 Million IPO
06/27 GOLDMAN SACHS GROUP : Fair Total Return For This Investment Bank
Advertisement
Financials ($)
Sales 2017 75 604 M
EBIT 2017 23 480 M
Net income 2017 17 895 M
Debt 2017 8 106 M
Yield 2017 2,49%
P/E ratio 2017 20,59
P/E ratio 2018 18,50
EV / Sales 2017 4,92x
EV / Sales 2018 4,68x
Capitalization 363 694 M
More Financials
Chart JOHNSON & JOHNSON
Duration : Period :
Johnson & Johnson Technical Analysis Chart | JNJ | US4781601046 | 4-Traders
Full-screen chart
Technical analysis trends JOHNSON & JOHNSON
Short TermMid-TermLong Term
TrendsBullishBullishBullish
Technical analysis
Income Statement Evolution
More Financials
Consensus
Sell
Buy
Mean consensus OUTPERFORM
Number of Analysts 21
Average target price 132 $
Spread / Average Target -2,4%
Consensus details
EPS Revisions
More Estimates Revisions
Managers
NameTitle
Alex Gorsky Chairman & Chief Executive Officer
Dominic J. Caruso Chief Financial Officer & Vice President
Paulus Stoffels Chief Scientific Officer & Executive VP
Charles O. Prince Independent Director
William David Perez Independent Director
More about the company
Sector and Competitors
1st jan.Capitalization (M$)
JOHNSON & JOHNSON18.34%363 694
ROCHE HOLDING LTD.8.21%224 549
NOVARTIS12.55%222 848
PFIZER3.97%201 105
MERCK AND COMPANY11.33%179 263
SANOFI13.95%125 371
More Results